Mark Pollack to Diagnostic and Statistical Manual of Mental Disorders
This is a "connection" page, showing publications Mark Pollack has written about Diagnostic and Statistical Manual of Mental Disorders.
Connection Strength
1.112
-
Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol. 2003 Jun; 23(3):250-9.
Score: 0.230
-
Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009 Nov; 70(11):1563-70.
Score: 0.089
-
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008 May; 65(5):551-62.
Score: 0.081
-
Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008 Oct; 42(14):1176-84.
Score: 0.080
-
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry. 2008 Mar; 69(3):400-5.
Score: 0.080
-
Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
Score: 0.079
-
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl). 2007 Oct; 194(2):233-42.
Score: 0.076
-
The relationship of anxiety disorders, anxiety sensitivity and pulmonary dysfunction with dyspnea-related distress and avoidance. J Nerv Ment Dis. 2006 Dec; 194(12):951-7.
Score: 0.073
-
An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
Score: 0.070
-
Bupropion sustained release for panic disorder. Psychopharmacol Bull. 2003; 37(4):66-72.
Score: 0.056
-
Impact of intensive treatment programs for posttraumatic stress disorder on suicidal ideation in veterans and service members. Psychol Serv. 2021 Nov; 18(4):671-678.
Score: 0.050
-
Redefining affective disorders: relevance for drug development. CNS Neurosci Ther. 2008; 14(1):2-9.
Score: 0.020
-
Cross-cultural differences in somatic presentation in patients with generalized anxiety disorder. J Nerv Ment Dis. 2006 Dec; 194(12):962-6.
Score: 0.018
-
Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry. 2005 Jun; 66(6):730-5; quiz 808-9.
Score: 0.017
-
Parental predictors of pediatric panic disorder/agoraphobia: a controlled study in high-risk offspring. Depress Anxiety. 2005; 22(3):114-20.
Score: 0.016
-
Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD. J Clin Psychopharmacol. 2004 Oct; 24(5):512-20.
Score: 0.016
-
Olfactory-triggered panic attacks among Cambodian refugees attending a psychiatric clinic. Gen Hosp Psychiatry. 2004 Sep-Oct; 26(5):390-7.
Score: 0.016
-
Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
Score: 0.016
-
Moderating effects of major depression on patterns of comorbidity in patients with panic disorder. Psychiatry Res. 2004 Apr 30; 126(2):143-9.
Score: 0.015
-
Exploring the psychometric properties and construct validity of the MCMI-III anxiety and avoidant personality scales. J Pers Assess. 2003 Dec; 81(3):237-41.
Score: 0.015